ArticleInvestigational new drugs2014

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors.

S Tjulandin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.